Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The bioavailability of phenytoin

R Gugler, W Fröscher, M Eichelbaum

    Journal of Neurology
    |October 7, 1977
    PubMed
    Summary

    Three phenytoin brands (Epanutin, Phenhydan, Zentropil) demonstrated equivalent bioavailability, making them interchangeable for epilepsy treatment. However, a standard sodium phenytoin solution showed higher bioavailability than these commercial products.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In situ optical sequencing and structure analysis of a trinucleotide repeat genome region by localization microscopy after specific COMBO-FISH nano-probing.

    Nanoscale·2015
    Same author

    Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

    The pharmacogenomics journal·2014
    Same author

    CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

    Clinical pharmacology and therapeutics·2013
    Same author

    [Pharmacogenetics: current state after 30 years of research].

    Deutsche medizinische Wochenschrift (1946)·2013
    Same author

    [Information needs of patients with prostate cancer. Pronounced differences between individuals after diagnosis of localised prostate carcinoma].

    Der Urologe. Ausg. A·2011
    Same author

    Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

    Clinical pharmacology and therapeutics·2011

    Area of Science:

    • Pharmacokinetics
    • Drug Bioavailability
    • Epilepsy Treatment

    Background:

    • Phenytoin is a widely used antiepileptic drug.
    • Ensuring consistent therapeutic outcomes requires understanding the bioavailability of different phenytoin formulations.
    • Commercial products vary in salt form (sodium, calcium, free acid), potentially affecting absorption.

    Purpose of the Study:

    • To compare the bioavailability of three commercial phenytoin products against a standard sodium phenytoin solution.
    • To determine if Epanutin, Phenhydan, and Zentropil are bioequivalent and interchangeable for antiepileptic therapy.

    Main Methods:

    • A crossover study design was employed, administering 300 mg daily doses of each phenytoin preparation for 14 days.
    • Plasma concentrations, area under the plasma-time curve (AUC), time to peak concentration (Tmax), and urinary metabolite excretion were measured.
    • Comparison was made against a standard sodium phenytoin solution.

    Main Results:

    • The three commercial phenytoin brands (Epanutin, Phenhydan, Zentropil) exhibited equivalent bioavailability.
    • Parameters such as plasma concentrations, AUC, Tmax, and metabolite excretion were similar across the tested brands.
    • The standard sodium phenytoin solution demonstrated higher bioavailability compared to the commercial products.

    Conclusions:

    • Epanutin, Phenhydan, and Zentropil are bioequivalent and can be considered interchangeable for antiepileptic treatment.
    • Healthcare providers can confidently switch between these phenytoin formulations.
    • A standard sodium phenytoin solution may offer superior bioavailability, warranting consideration in clinical practice.

    Related Experiment Videos